

Adrian J Hobbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4114437/publications.pdf>

Version: 2024-02-01

57
papers

4,627
citations

186265

28
h-index

182427

51
g-index

57
all docs

57
docs citations

57
times ranked

5196
citing authors

#	ARTICLE	IF	CITATIONS
1	Animal models of pulmonary hypertension: Getting to the heart of the problem. <i>British Journal of Pharmacology</i> , 2022, 179, 811-837.	5.4	31
2	Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. <i>Cardiovascular Research</i> , 2022, 118, 2085-2102.	3.8	23
3	Hydropersulfides (RSSH) and Nitric Oxide (NO) Signaling: Possible Effects on S-Nitrosothiols (RS-NO). <i>Antioxidants</i> , 2022, 11, 169.	5.1	11
4	A Series of Substituted Bis-Aminotriazines Are Activators of the Natriuretic Peptide Receptor C. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5495-5513.	6.4	2
5	C-type natriuretic peptide is a pivotal regulator of metabolic homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2116470119.	7.1	9
6	The reaction of hydropersulfides (RSSH) with S-nitrosothiols (RS-NO) and the biological/physiological implications. <i>Free Radical Biology and Medicine</i> , 2022, 188, 459-467.	2.9	5
7	A comparison of the chemical biology of hydropersulfides (RSSH) with other protective biological antioxidants and nucleophiles. <i>Nitric Oxide - Biology and Chemistry</i> , 2021, 107, 46-57.	2.7	25
8	The role of cGMP signalling in auditory processing in health and disease. <i>British Journal of Pharmacology</i> , 2021, , .	5.4	3
9	Multidrug resistance proteins preferentially regulate natriuretic peptide-driven cGMP signalling in the heart & vasculature. <i>British Journal of Pharmacology</i> , 2021, , .	5.4	6
10	Innovative Anti-Inflammatory and Pro-resolving Strategies for Pulmonary Hypertension: High Blood Pressure Research Council of Australia Award 2019. <i>Hypertension</i> , 2021, 78, 1168-1184.	2.7	6
11	C-type natriuretic peptide co-ordinates cardiac structure and function. <i>European Heart Journal</i> , 2020, 41, 1006-1020.	2.2	56
12	Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 370-384.	1.9	16
13	Vascular KATP channels protect from cardiac dysfunction and preserve cardiac metabolism during endotoxemia. <i>Journal of Molecular Medicine</i> , 2020, 98, 1149-1160.	3.9	2
14	Combination of cyclic nucleotide modulators with P2Y 12 receptor antagonists as anti-platelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1705-1713.	3.8	3
15	Inflammasomes: a novel therapeutic target in pulmonary hypertension?. <i>British Journal of Pharmacology</i> , 2019, 176, 1880-1896.	5.4	31
16	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors. <i>British Journal of Pharmacology</i> , 2019, 176, S247-S296.	5.4	156
17	C-Type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2281.	4.1	93
18	Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial. <i>British Journal of Pharmacology</i> , 2019, 176, 1251-1267.	5.4	20

#	ARTICLE	IF	CITATIONS
19	Biophysical screening methods for extracellular domain peptide receptors, application to natriuretic peptide receptor C ligands. <i>Chemical Biology and Drug Design</i> , 2019, 93, 1011-1020.	3.2	3
20	Endothelial C-Type Natriuretic Peptide Is a Critical Regulator of Angiogenesis and Vascular Remodeling. <i>Circulation</i> , 2019, 139, 1612-1628.	1.6	58
21	Nitric oxide biology & pathobiology (3rd edition) editors: Louis Ignarro & Bruce Freeman. <i>Nitric Oxide - Biology and Chemistry</i> , 2019, 90, 66.	2.7	6
22	The biological impact of blood pressure-associated genetic variants in the natriuretic peptide receptor C gene on human vascular smooth muscle. <i>Human Molecular Genetics</i> , 2018, 27, 199-210.	2.9	21
23	Potent Anti-inflammatory and Pro-resolving Effects of Anabasum in a Human Model of Self-resolving Acute Inflammation. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 675-686.	4.7	52
24	Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7428-E7437.	7.1	33
25	Biological hydropersulfides and related polysulfides – a new concept and perspective in redox biology. <i>FEBS Letters</i> , 2018, 592, 2140-2152.	2.8	164
26	Guanylyl cyclase can't stand the HETE. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H1608-H1610.	3.2	0
27	Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy. <i>International Journal of Cardiology</i> , 2016, 219, 177-179.	1.7	32
28	Functional pharmacological characterization of SER100 in cardiovascular health and disease. <i>British Journal of Pharmacology</i> , 2016, 173, 3386-3401.	5.4	7
29	A Janus-Faced Role for Atrial Natriuretic Peptide in Myocardial Infarction?. <i>Circulation Research</i> , 2016, 119, 181-183.	4.5	0
30	Raised arterial blood pressure in neurokinin-1 receptor-deficient mice (<i>NK1R</i> ^{-/-}): evidence for a neural rather than a vascular mechanism. <i>Experimental Physiology</i> , 2016, 101, 588-598.	2.0	4
31	The nuances of NO synthase regulation in sepsis: Could targeting BH4 be the answer?. <i>Vascular Pharmacology</i> , 2016, 77, 35-37.	2.1	1
32	Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. <i>British Journal of Pharmacology</i> , 2015, 172, 1397-1414.	5.4	29
33	Modulation of cGMP Synthesis and Metabolism. <i>Respiratory Medicine</i> , 2015, , 355-375.	0.1	1
34	Investigation of the Role of Multidrug Resistance Proteins (MRPs) in Vascular Homeostasis. <i>FASEB Journal</i> , 2015, 29, 783.8.	0.5	0
35	Abstract 19478: Endothelial and Cardiomyocyte -derived C-type Natriuretic Peptide Coordinate Heart Structure and Function. <i>Circulation</i> , 2015, 132, .	1.6	0
36	Inhibition of Phosphodiesterase 2 Augments cGMP and cAMP Signaling to Ameliorate Pulmonary Hypertension. <i>Circulation</i> , 2014, 130, 496-507.	1.6	63

#	ARTICLE	IF	CITATIONS
37	Redox chemistry and chemical biology of H ₂ S, hydropersulfides, and derived species: Implications of their possible biological activity and utility. <i>Free Radical Biology and Medicine</i> , 2014, 77, 82-94.	2.9	340
38	Endothelial C-type natriuretic peptide maintains vascular homeostasis. <i>Journal of Clinical Investigation</i> , 2014, 124, 4039-4051.	8.2	125
39	Letter by Ahluwalia and Hobbs Regarding Article, "Nitrate-Nitrite-Nitric Oxide Pathway in Pulmonary Arterial Hypertension Therapeutics". <i>Circulation</i> , 2013, 127, e275.	1.6	0
40	Dietary Nitrate Ameliorates Pulmonary Hypertension. <i>Circulation</i> , 2012, 125, 2922-2932.	1.6	104
41	New perspectives for the treatment of pulmonary hypertension. <i>British Journal of Pharmacology</i> , 2011, 163, 125-140.	5.4	52
42	Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide. <i>British Journal of Pharmacology</i> , 2011, 164, 584-597.	5.4	47
43	Inorganic Nitrate Supplementation Lowers Blood Pressure in Humans. <i>Hypertension</i> , 2010, 56, 274-281.	2.7	502
44	The antiatherogenic potential of C-type natriuretic peptide: Disparate regulation of endothelial and vascular smooth muscle cell proliferation via natriuretic peptide receptor-3. <i>FASEB Journal</i> , 2010, 24, 573.4.	0.5	0
45	The Effects of Nitroxyl (HNO) on Soluble Guanylate Cyclase Activity. <i>Journal of Biological Chemistry</i> , 2009, 284, 21788-21796.	3.4	94
46	NO-Independent, Haem-Dependent Soluble Guanylate Cyclase Stimulators. <i>Handbook of Experimental Pharmacology</i> , 2009, , 277-308.	1.8	171
47	Acute Blood Pressure Lowering, Vasoprotective, and Antiplatelet Properties of Dietary Nitrate via Bioconversion to Nitrite. <i>Hypertension</i> , 2008, 51, 784-790.	2.7	885
48	Mechanisms Underlying Erythrocyte and Endothelial Nitrite Reduction to Nitric Oxide in Hypoxia. <i>Circulation Research</i> , 2008, 103, 957-964.	4.5	166
49	Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor. <i>Journal of Endocrinology</i> , 2008, 197, 447-462.	2.6	59
50	Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 861-869.	5.6	59
51	Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. <i>Cardiovascular Research</i> , 2007, 74, 515-525.	3.8	85
52	Investigation of Vascular Responses in Endothelial Nitric Oxide Synthase/Cyclooxygenase-1 Double-Knockout Mice. <i>Circulation</i> , 2005, 111, 796-803.	1.6	197
53	C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14452-14457.	7.1	87
54	Natriuretic Peptide Receptor-C Regulates Coronary Blood Flow and Prevents Myocardial Ischemia/Reperfusion Injury. <i>Circulation</i> , 2004, 110, 1231-1235.	1.6	134

#	ARTICLE	IF	CITATIONS
55	Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. <i>British Journal of Pharmacology</i> , 2003, 139, 1289-1296.	5.4	63
56	Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1426-1431.	7.1	217
57	Soluble guanylate cyclase: the forgotten sibling. <i>Trends in Pharmacological Sciences</i> , 1997, 18, 484-491.	8.7	268